Thorac Cardiovasc Surg 2017; 65(S 01): S1-S110
DOI: 10.1055/s-0037-1598840
Oral Presentations
Monday, February 13th, 2017
DGTHG: Terminal Heart and Lung Failure - LVAD: Clinical Results with Different Devices
Georg Thieme Verlag KG Stuttgart · New York

First Experience with the HeartAssist5® Left Ventricular Assist Device

E. Deniz
1   Hannover Medical School, Cardiac, Thoracic, Transplant and Vascular Surgery, Hannover, Germany
,
J.S. Hanke
1   Hannover Medical School, Cardiac, Thoracic, Transplant and Vascular Surgery, Hannover, Germany
,
F. Schwick
1   Hannover Medical School, Cardiac, Thoracic, Transplant and Vascular Surgery, Hannover, Germany
,
S.V. Rojas-Hernandez
1   Hannover Medical School, Cardiac, Thoracic, Transplant and Vascular Surgery, Hannover, Germany
,
G. Dogan
1   Hannover Medical School, Cardiac, Thoracic, Transplant and Vascular Surgery, Hannover, Germany
,
C. Feldmann
1   Hannover Medical School, Cardiac, Thoracic, Transplant and Vascular Surgery, Hannover, Germany
,
U. Molitoris
1   Hannover Medical School, Cardiac, Thoracic, Transplant and Vascular Surgery, Hannover, Germany
,
C. Fegbeutel
1   Hannover Medical School, Cardiac, Thoracic, Transplant and Vascular Surgery, Hannover, Germany
,
C. Bara
1   Hannover Medical School, Cardiac, Thoracic, Transplant and Vascular Surgery, Hannover, Germany
,
M. Shrestha
1   Hannover Medical School, Cardiac, Thoracic, Transplant and Vascular Surgery, Hannover, Germany
,
A. Haverich
1   Hannover Medical School, Cardiac, Thoracic, Transplant and Vascular Surgery, Hannover, Germany
,
J.D. Schmitto
1   Hannover Medical School, Cardiac, Thoracic, Transplant and Vascular Surgery, Hannover, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
03 February 2017 (online)

 
  All articles of this category

    Objectives: The objective of this study was to describe the operative experience as well as short and long -term outcomes of patients implanted with the HeartAssist5® (HA5)-Left Ventricular Assist Device (LVAD) during June 2015 and May 2016.

    Methods: Adult patients met inclusion and exclusion criteria defining advanced-stage heart failure and included the indications of bridge to transplant (BTT) or destination therapy (DT). Operative parameters, survival and adverse events were assessed in the first 30 days after LVAD implant and during long- term follow up (3, 6 and 12 months).

    Results: Six patients were implanted with the HA5 at Hannover Medical School. 5 male, 1 female, mean age 61 years (range: 58–70), main diagnosis DCM (67%). LVAD indication was BTT in 5 (83%) cases and DT in 1 (17%) case; Five patients (74%) were INTERMACS class 1 or 2. 5 implantations performed in median sternotomy and 1 in minimal invasive “Hannover approach” technique. In 2 cases there were combined operative procedures. The 30-day survival rate was 100%. The median operative time was 206 (range: 150–330) min and the median cardiopulmonary bypass time was 101 (range: 60–148) min, respectively. All patients required transfusion with packed red blood cells, fresh frozen plasma and platelets during operation. One patient (17%) required reoperation for postoperative bleeding. The median intensive care time was 3.6 days (range: 1–8 days) and the total hospital stay was 24 days (range: 13–32 days). There was no adverse event in 30 days after LVAD implant. The most common adverse events during long term follow up (max. 1 year) were suspected pump thrombosis (2, 33%), bleeding (2, 33%) and stroke (1, 17%). There was 1 (17%) controller dysfunction, no infection, no proved pump thrombosis and no death in -year follow up. One patient received heart transplantation after VAD implantation.

    Conclusion: The short- and long-term outcomes following implantation of the HA5-LVAD demonstrates excellent survival with comparable adverse event rates.


    #

    No conflict of interest has been declared by the author(s).

       All articles of this category